Table 1.
Demographic profile
| All patients, n=140 | Retrospective cohort, n=75 | Prospective cohort, n=65 | P value | |
| Age in years, mean (SD) | 39.6 (12.8) | 39.6 (12.4) | 39.5 (13.1) | 0.80 |
| Male sex | 94 (67.1%) | 51 (68%) | 43 (67%) | 0.81 |
| Diabetes | 7 (5%) | 3 (4%) | 4 (6.3%) | 0.55 |
| Hypertension | 25 (17.9%) | 15 (20%) | 10 (15.6%) | 0.51 |
| Current smokers | 51 (34.4%) | 27 (36%) | 24 (37.5%) | 0.88 |
| PLHIV | 32 (22.9%) | 14 (21.5%) | 18 (29%) | 0.21 |
| CD4 count in cells/µL, median (Q1;Q3) | 423 | 442 (137;568) | 409 (204;568) | 0.96 |
| c-ART | 23 (71.8%) | 10/14 (71.4%) | 13/18 (72%) | 0.98 |
| History of intravenous drug use | 10 (7.1%) | 5 (6.7%) | 5 (7.7%) | 0.93 |
| History of valvular heart disease | 40 (28.6%) | 24 (32%) | 16 (25%) | 0.37 |
| Previous cardiac surgery | 20 (14.3%) | 10 (13.3%) | 10 (15.6%) | 0.70 |
| Definite IE by the modified Duke/ ESC 2015 clinical criteria2 | 83 (59.3%) | 35 (46.7%) | 48 (73.8%) | <0.01 |
c-ART, combination anti-retroviral therapy; IE, infective endocarditis; PLHIV, people living with HIV.